Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

AD-214 - AdAlta

http://www.ncbi.nlm.nih.gov/pubmed/40395177

Angus Tester; Chris Hosking; Dallas J Hartman; Jason P Lynch; Khamis Tomusange; Louise Organ; Lukasz Kowalczyk; Michael Foley

May 21, 2025